Utility of inhaled nitric oxide for pulmonary hypertension in cyanotic congenital heart disease: a cohort study with propensity score matching

Xiaofeng Wang, Chenyu Li, Shilin Wang, Zhiyuan Zhu, Qinnan Chen, Ruihuan Shen, Xu Wang
National Center for Cardiovascular Disease and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences amd Affiliated Cardiovascular Hospital of Kunming Medical University. Sir Run Run Shaw Hospital and Zhejiang University School of Medicine.
China

Medical Gas Research
Med Gas Res 2025; 16:
DOI: 10.4103/mgr.MEDGASRES-D-25-00062

Abstract
Pulmonary hypertension can lead to hemodynamic instability and worsen the outcome after the repair of cyanotic congenital heart disease with decreased pulmonary blood flow. However, the safety and effectiveness of targeted therapy, such as inhaled nitric oxide, remain controversial. This retrospective cohort study included patients who underwent corrective repair for tetralogy of Fallot, double outlet right ventricle, or pulmonary atresia with ventricular septal defect with hypoplastic pulmonary vasculature at Fuwai Hospital between 2014 and 2021. Patients were divided into a regular treatment group and a combined treatment group depending on whether inhaled nitric oxide was prescribed. The improvement in low cardiac output syndrome within 24 hours after surgery and the main clinical outcomes during hospitalization were compared between the two groups after 1:1 propensity score matching. Compared with those in the regular treatment group, both the incidence of low cardiac output syndrome and the rate of renal replacement therapy were lower in the combined treatment group. Inhaled nitric oxide therapy is effective in the treatment of patients with pulmonary hypertension after corrective repair of cyanotic congenital heart disease.

Category
Class I. Pulmonary Hypertension Associated with Congenital Cardiovascular Disease
Medical Therapy. Efficacy or Lack of Efficacy

Age Focus: Pediatric Pulmonary Vascular Disease

Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication

Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes

Scroll to Top